BG106833A - Фулвестрантов състав - Google Patents

Фулвестрантов състав

Info

Publication number
BG106833A
BG106833A BG106833A BG10683302A BG106833A BG 106833 A BG106833 A BG 106833A BG 106833 A BG106833 A BG 106833A BG 10683302 A BG10683302 A BG 10683302A BG 106833 A BG106833 A BG 106833A
Authority
BG
Bulgaria
Prior art keywords
oestra
7alpha
17beta
triene
nonyl
Prior art date
Application number
BG106833A
Other languages
English (en)
Other versions
BG65776B1 (bg
Inventor
John Evans
Rosalind GRUNDY
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG106833(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BG106833A publication Critical patent/BG106833A/bg
Publication of BG65776B1 publication Critical patent/BG65776B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до нов фармацевтичен състав с удължено освобождаване, адаптиран за приложение чрез инжектиране, съдържащ съединението 7 алфа-[9-(4,4,5,5,5-пентафлуоропентилсулфинил) нонил] естра-1,3,5-(10)-триен-3,17 бета-диол, по-специалнодо състав, адаптиран за приложение чрез инжектиране, съдържащ посоченото съединение в разтвор в рицинолеатен вехикулум, който допълнително съдържа поне един алкохол и неводен естерен разтворител, смесващ се с вехикулума.
BG106833A 2000-01-10 2002-06-18 Фулвестрантов състав BG65776B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation

Publications (2)

Publication Number Publication Date
BG106833A true BG106833A (bg) 2003-03-31
BG65776B1 BG65776B1 (bg) 2009-11-30

Family

ID=26243352

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106833A BG65776B1 (bg) 2000-01-10 2002-06-18 Фулвестрантов състав

Country Status (41)

Country Link
US (5) US20030125387A1 (bg)
EP (4) EP1250138B2 (bg)
JP (3) JP3713237B2 (bg)
KR (1) KR100802366B1 (bg)
CN (1) CN1222292C (bg)
AR (1) AR027510A1 (bg)
AT (1) ATE306928T1 (bg)
AU (1) AU762080B2 (bg)
BE (1) BE1013477A3 (bg)
BG (1) BG65776B1 (bg)
BR (1) BR0107445B1 (bg)
CA (1) CA2351004C (bg)
CH (1) CH696260A5 (bg)
CO (1) CO5280206A1 (bg)
CY (1) CY1116520T1 (bg)
CZ (1) CZ304689B6 (bg)
DE (2) DE60114145T3 (bg)
DK (2) DK1250138T4 (bg)
EE (1) EE05421B1 (bg)
EG (1) EG24074A (bg)
ES (3) ES2543384T3 (bg)
FR (1) FR2803516B1 (bg)
GB (3) GB0000313D0 (bg)
HK (3) HK1049286B (bg)
HU (1) HU230162B1 (bg)
IL (2) IL150230A0 (bg)
IS (1) IS2932B (bg)
IT (2) ITTO20010005A1 (bg)
MX (1) MXPA02006698A (bg)
MY (1) MY118583A (bg)
NL (1) NL1017075C2 (bg)
NO (2) NO336286B1 (bg)
PL (1) PL202525B1 (bg)
PT (2) PT2266573E (bg)
RU (1) RU2263507C9 (bg)
SI (2) SI1250138T2 (bg)
SK (1) SK287221B6 (bg)
TW (1) TWI259086B (bg)
UA (1) UA75879C2 (bg)
WO (1) WO2001051056A1 (bg)
ZA (1) ZA200204165B (bg)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
PL367624A1 (en) * 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
EP1928469A4 (en) * 2005-09-26 2008-12-31 Hospira Australia Pty Ltd Fulvestrant FORMULATION
KR20100121505A (ko) 2008-03-07 2010-11-17 싸이도우스 엘엘씨. 플배스트랜 제제
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
DK2580210T5 (en) 2010-06-10 2017-06-19 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
PT2616078T (pt) 2010-09-16 2020-03-31 Shimoda Biotech Pty Ltd Composições de fulvestrant e métodos de uso
CA2836831C (en) * 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
JP6112625B2 (ja) 2011-12-14 2017-04-12 セラゴン ファーマシューティカルズ，インク． フッ素化したエストロゲン受容体モジュレーターおよびその使用
WO2013090921A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
EP2836199B1 (en) * 2012-04-09 2024-06-19 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2013386732B2 (en) 2013-04-18 2018-10-18 Xi'an Libang Pharmaceutical Technology Co., Ltd. Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
EP3041512A4 (en) * 2013-09-06 2017-05-10 Ahmed, Salah U. Fulvestrant compositions
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
ES2819448T3 (es) 2014-12-18 2021-04-16 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018003929A (es) 2015-10-01 2018-11-22 Olema Pharmaceuticals Inc Fármacos anti-estrogénicos tetrahidro-1h-pirido [3,4-b] indol.
JP2018530597A (ja) 2015-10-13 2018-10-18 テミス メディケア リミティド フルベストラント組成物
MX2020006991A (es) 2015-12-09 2022-07-14 Univ Illinois Reguladores a la baja del receptor de estrógeno selectivo de benzotiofeno.
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017175810A1 (ja) * 2016-04-06 2017-10-12 富士フイルム株式会社 医薬組成物
CN109219604B (zh) 2016-04-08 2021-09-24 豪夫迈·罗氏有限公司 四氢异喹啉雌激素受体调节剂及其用途
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP2019516789A (ja) * 2016-05-06 2019-06-20 イーグル ファーマスーティカルズ、インク． フルベストラント配合物およびその使用方法
WO2017208847A1 (ja) * 2016-05-31 2017-12-07 富士フイルム株式会社 医薬組成物
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
WO2017216279A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
WO2017216280A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
TW202428251A (zh) 2017-09-11 2024-07-16 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
KR102670293B1 (ko) * 2017-11-08 2024-05-30 이글 파마슈티컬즈 인코포레이티드 풀베스트란트 제제 및 그의 사용 방법
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
WO2019224790A2 (en) 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Prodrugs of fulvestrant
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
WO2020093006A1 (en) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3924054A1 (en) 2019-02-15 2021-12-22 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20230092679A1 (en) 2019-05-20 2023-03-23 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
EP4074304A4 (en) * 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
IL303059A (en) 2020-11-24 2023-07-01 Novartis Ag Antibodies against CD48, antibody-drug conjugates and uses thereof
IL303079A (en) 2020-11-24 2023-07-01 Novartis Ag Antibody-drug conjugates inhibiting MCL-1 and methods of using them
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
KR20230094172A (ko) * 2021-12-20 2023-06-27 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) † 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (bg) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
NL7711916A (nl) * 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5952338A (en) 1996-07-05 1999-09-14 Takeda Chemical Industries, Ltd. Agent for prophylaxis and treatment of disturbance of visual function
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
ATE249206T1 (de) 1997-12-03 2003-09-15 Merck & Co Inc Langwirkende, injizierbare, formulierungen enthaltend rizinusöl
EP2266537B1 (en) 1999-04-01 2014-09-03 Hana Biosciences, Inc. Compositions for treating cancer
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
PL367624A1 (en) 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
IS6454A (is) 2002-07-03
CY1116520T1 (el) 2017-03-15
NO20150741L (no) 2002-07-03
DK1250138T3 (da) 2006-01-23
HK1052884B (zh) 2006-07-14
ITTO20010005A1 (it) 2001-07-11
PL202525B1 (pl) 2009-07-31
RU2263507C2 (ru) 2005-11-10
PL356030A1 (en) 2004-06-14
NO337329B1 (no) 2016-03-14
BR0107445B1 (pt) 2012-10-30
CO5280206A1 (es) 2003-05-30
EP2266573A1 (en) 2010-12-29
ES2248272T5 (es) 2015-08-19
NO20023227L (no) 2002-07-03
PT102548A (pt) 2001-07-31
FR2803516B1 (fr) 2003-03-28
MXPA02006698A (es) 2002-09-30
ZA200204165B (en) 2003-10-29
DK2266573T3 (en) 2015-07-20
GB0008837D0 (en) 2000-05-31
HK1049286A1 (en) 2003-05-09
US8329680B2 (en) 2012-12-11
MY118583A (en) 2004-12-31
EP1669073A2 (en) 2006-06-14
DE60114145T2 (de) 2006-07-13
US20050043285A1 (en) 2005-02-24
JP2011190275A (ja) 2011-09-29
EP2286818A1 (en) 2011-02-23
DK1250138T4 (en) 2015-07-27
ATE306928T1 (de) 2005-11-15
ES2543384T3 (es) 2015-08-18
AR027510A1 (es) 2003-04-02
KR100802366B1 (ko) 2008-02-13
TWI259086B (en) 2006-08-01
NL1017075A1 (nl) 2001-07-11
SK287221B6 (sk) 2010-03-08
WO2001051056A1 (en) 2001-07-19
CA2351004C (en) 2003-02-18
UA75879C2 (en) 2006-06-15
US20030125387A1 (en) 2003-07-03
KR20020073499A (ko) 2002-09-26
GB0100407D0 (en) 2001-02-21
US8466139B2 (en) 2013-06-18
EG24074A (en) 2008-05-11
DE10100779A1 (de) 2001-07-26
CN1394141A (zh) 2003-01-29
ES2186517B2 (es) 2004-03-16
HUP0204137A3 (en) 2005-03-29
SI1250138T1 (sl) 2006-02-28
NO336286B1 (no) 2015-07-13
US7456160B2 (en) 2008-11-25
GB2359254B (en) 2002-06-19
EP1250138B1 (en) 2005-10-19
RU2002121507A (ru) 2004-03-20
JP3713237B2 (ja) 2005-11-09
SK9842002A3 (en) 2003-05-02
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
IL150230A0 (en) 2002-12-01
ES2186517A1 (es) 2003-05-01
NL1017075C2 (nl) 2001-09-25
DE60114145D1 (de) 2006-03-02
EE05421B1 (et) 2011-06-15
PT2266573E (pt) 2015-07-28
HK1049286B (zh) 2006-04-07
BE1013477A3 (fr) 2002-02-05
AU2386301A (en) 2001-07-24
ES2248272T3 (es) 2006-03-16
HU230162B1 (hu) 2015-09-28
EE200200387A (et) 2003-10-15
JP2003519659A (ja) 2003-06-24
BG65776B1 (bg) 2009-11-30
SI1250138T2 (sl) 2015-09-30
FR2803516A1 (fr) 2001-07-13
BR0107445A (pt) 2002-09-17
EP1250138B2 (en) 2015-07-08
US20120329766A1 (en) 2012-12-27
AU762080B2 (en) 2003-06-19
DE60114145T3 (de) 2015-09-17
GB2359254A (en) 2001-08-22
US20100152149A1 (en) 2010-06-17
IS2932B (is) 2015-12-15
HK1052884A1 (en) 2003-10-03
RU2263507C9 (ru) 2020-07-28
NO20023227D0 (no) 2002-07-03
ITTO20010008A1 (it) 2002-07-10
CA2351004A1 (en) 2001-07-10
CZ20022384A3 (cs) 2002-09-11
EP1669073A3 (en) 2008-03-19
CZ304689B6 (cs) 2014-09-03
IL150230A (en) 2006-10-31
EP2286818B1 (en) 2020-03-18
US20010020016A1 (en) 2001-09-06
EP1250138A1 (en) 2002-10-23
JP2004107353A (ja) 2004-04-08
EP2266573B1 (en) 2015-06-17
HUP0204137A2 (hu) 2003-04-28
CH696260A5 (de) 2007-03-15
US6774122B2 (en) 2004-08-10
SI2266573T1 (sl) 2015-08-31
CN1222292C (zh) 2005-10-12
GB0000313D0 (en) 2000-03-01
HK1150021A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
BG106833A (bg) Фулвестрантов състав
CY1107142T1 (el) Τυποποιηση που περιλαμβανει fulvestrant
MXPA04000028A (es) Formulacion farmaceutica para la administracion intramuscular de fulvestrant.
EP2266590A3 (en) Active agent delivery sytems and methods for protecting and administering active agents
SI2348032T1 (sl) S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)-11beta-hidroksi- 16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
WO2003022252A3 (en) Combinatorial type (several vehicles within a housing) controlled release drug delivery device
YU58000A (sh) Preparati sa neprekidnim oslobađanjem
WO2003105767A3 (en) ANTIFUNGAL PARENTERAL PRODUCTS
EP1074243A3 (en) Cosmetic compositions
WO1999053910A3 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
IL166432A0 (en) Composition containing an androgenous 11?-halogen steroid and a progestational hormone and male contraceptive based on said composition
NZ510469A (en) Injectable propofol formulations containing N-methyl pyrrolidone or 2-methyl pyrrolidone as a solvent
AU2001283359A1 (en) Drug release (delivery system)
WO2001068102A3 (en) Nystatin formulation having reduced toxicity
WO2002015959A3 (en) Compounds and compositions for delivering active agents
DE69901250D1 (de) 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität
WO2004004639A3 (en) A novel stable formulation
WO2002100338A3 (en) Compound and composition for delivering active agents
AU2001242328A1 (en) Formulations of active components in the form of a solid dispersion
AR018888A1 (es) Un derivado de testosterona, uso del mismo, una formulacion farmaceutica que comprende a dicho derivado y un kit para la anticoncepcion masculina
SE9902742D0 (sv) New pharmaceutical formultion
EP1232740A3 (en) Hair-growing agent
PE20010581A1 (es) Mesoprogestinas (modulares de receptores de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (hrt)
WO2004078677A3 (en) Enhanced delivery of sphingolipids
WO2004058141A3 (en) An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component